Refresh your memory on findings from the EMPA-REG OUTCOME, CANVAS, CREDENCE, and DECLARE-TIMI cardiovascular outcomes trials on SGLT2 inhibitors.
Cardiovascular (CV) outcomes trials have generally shown that sodium–glucose cotransporter 2 inhibitors (SGLT2i) decrease CV risk in patients with type 2 diabetes mellitus (T2DM). Major CV outcomes randomized controlled trials (RCTs) for this class of drugs include:
Test your knowledge on the 4 major CV outcomes RCTs for SGLT2i with the 8-question quiz below.
1. Which trial failed to find significantly decreased 3-point major adverse CV events (MACE) in patients with T2DM?
A. EMPA-REG OUTCOME